LA JOLLA, Calif. (March 26, 2018) – INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient’s innate immune system, announces that Mark Lowdell, Ph.D., professor of Cell and Tissue Therapy at University College London and co-founder and chief scientific officer of INmune Bio, will participate as an expert speaker at the Third Annual Innate Killer Summit 2018 taking place March 27-29, 2018 in San Diego.
As part of the “Clinical Trial Case Studies” panel, Prof. Lowdell’s discussion, “Priming Human NK cells to Kill NK-Resistant Tumors in The Absence of IL-2,” will highlight the biology of tumor-mediated priming of natural killer (NK) cells, and will feature results from clinical trials in acute myeloid leukemia, as well as preclinical data that support the first trial of in vivo priming in metastatic ovarian cancer. The panel is on March 29 and begins at 2 p.m. PST.
"This international summit will emphasize the increasing importance of NK cells as novel immunotherapies for cancer treatment, and is a great opportunity to present data on INmune’s proprietary NK technology platform, INKmune, before an audience of fellow leading researchers in the field. INKmune is an off-the-shelf therapeutic that primes the patient’s own NK cells to attack their cancer. Importantly, the presentation will feature preclinical data that support our plans to advance INKmune to phase 1 clinical studies in metastatic ovarian cancer in the third quarter of 2018,” states Prof. Lowdell.
For more information on INKmune, visit: http://inmunebio.com/index.php/clinical/inkmune
About INmune Bio, Inc.
INmune Bio, Inc. is a clinical-stage biotechnology company developing therapies targeting the innate immune system. INmune Bio is developing two product platforms that reengineer the patient’s innate immune system’s response to their cancer, INKmune and INB03. INKmune is an NK cell therapeutic that primes the patient’s NK cells to attack their cancer. INB03 inhibits myeloid-derived suppressor cells, which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio’s product platforms reprogram the patient’s innate immune system to help it attack their cancer. The platforms can be used alone or as part of combination therapy to treat a variety of hematologic malignancies and solid tumors. To learn more, please visit www.INmuneBio.com.
INmune Bio Contact:
David Moss, CFO
LHA Investor Relations
Anne Marie Fields
Senior Vice President